Table 2 Cumulative prognostic scores and survival in patients with inoperable NSCLC (n=161): univariate survival analysis
CRP/stage | (n) | CRP | Stage | Cumulative scores | Survival (months) | Hazard ratio (95%CI) |
|---|---|---|---|---|---|---|
14 | ⩽10 mg l−l | III | 0 | 18.2 (14.5–21.9) | ||
15 | IV | 1 | 10.4 (7.9–12.8) | |||
43 | >10 mg l−l | III | 1 | 8.9 (5.5–12.3) | 1.73 (1.23–2.33) | |
89 | IV | 2 | 6.1 (3.4–8.7) | P<0.001 | ||
CRP/ECOG | CRP | ECOG | ||||
23 | ⩽10 mg l−l | 0–1 | 0 | 17.9 (15.5–20.3) | ||
6 | 2–4 | 1 | ||||
68 | >10 mg l−l | 0–1 | 1 | 9.0 (4.3–13.6) | 1.79 (1.37–2.35) | |
64 | 2–4 | 2 | 4.2 (2.2–6.2) | P<0.001 | ||
CRP/albumin | CRP | Albumin | ||||
27 | ⩽10 mg l−l | ⩾35 g l−1 | 0 | 17.0 (11.4–22.6) | ||
2 | <35 g l−1 | 1 | ||||
99 | >10 mg l−l | ⩾35 g l−1 | 1 | 8.9 (6.3–11.4) | 2.00 (1.47–2.70) | |
33 | <35 g l−1 | 2 | 3.9 (0.8–7.1) | P<0.001 | ||
Stage/ECOG | Stage | ECOG | ||||
40 | III | 0–1 | 0 | 16.1 (9.5–22.6) | ||
17 | 2–4 | 1 | 9.7 (3.5–15.8) | |||
51 | IV | 0–1 | 1 | 10.4 (5.8–14.9) | 1.73 (1.33–2.24) | |
53 | 2–4 | 2 | 3.6 (1.7–5.6) | P<0.001 |
